Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET
Company Participants
Sharon Klahre – Head, Investor Relations
Michael Metzger – Chief Executive Officer
Neil Gallagher – President & Head, R&D
Steve Closter – Chief Commercial Officer
Keith Goldan – Chief Financial Officer
Anjali Ganguli – Chief Strategy Officer
Conference Call Participants
Priyanka Grover – JPMorgan
Brad Canino – Stifel
Peter Lawson – Barclays
Chris Shibutani – Goldman Sachs
Kelly Shi – Jefferies
Phil Nadeau – TD Cowen
Michael Schmidt – Guggenheim
Ashiq Mubarack – Citi
Jason Zemansky – Bank of America
George Farmer – Scotiabank
Kalpit Patel – B. Riley Securities
Justin Zelin – BTIG
Operator
Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today’s call is being recorded. All participants have been placed in a listen-only mode. You’ll have an opportunity to ask questions after today’s presentation. [Operator Instructions]
At this time, I’d like to turn over the call to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Sharon Klahre
Great. Thank you, operator. Welcome, and thank you all for joining us today as we review Syndax’s third quarter 2024 financial and operating results.
I’m Sharon Klahre, and with me this afternoon to provide an update on the company’s progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; Steve Closter, Chief Commercial Officer; and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Strategy Officer.
This call is accompanied by a slide that has been posted on the Investor page of the company’s website.
You can now turn to our forward-looking statements on Slide 2. Before we begin, I’d
Read the full article here
